All In Biotech

Investigational drug · Phase 2

HMB-002

Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Von Willebrand Disease (VWD), Von Willebrand Disease (VWD), Type 1, Von Willebrand Disease (VWD), Type 2.

Phase 2

Last checked: Nov 19, 2026Latest source record: Jun 30, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations

Highest phase

Phase 2

Industry-sponsored trials

Phase 2 and 3 trials

1

1 still active

All registered trials

2

Any phase or sponsor naming "HMB-002"

First trial start

2025

Feb 6, 2025

Sponsors

Lead sponsors of its Phase 2 and 3 trials.

All registered trials by phase

Every ClinicalTrials.gov drug study naming "HMB-002", any sponsor or status.

Conditions studied

As listed on its trial records.

  • Von Willebrand Disease (VWD)
  • Von Willebrand Disease (VWD), Type 1
  • Von Willebrand Disease (VWD), Type 2
  • Von Willebrand Disease (VWD), Type 3

Approved drugs for the same conditions: Hematology and blood cancers

Largest trials

Live from ClinicalTrials.gov: studies naming "HMB-002" as an intervention, largest first.

All trials

Newest research

PubMed records naming it or its code names, newest first.

All 1 on PubMed

Also in development for Von Willebrand Disease (VWD)

  • SR604Phase 34 trials

    Shanghai RAAS Blood Products Co., Ltd. · Factor VII Deficiency, Hemophilia A, Hemophilia B

  • VGA039Phase 32 trials

    Vega Therapeutics, Inc · Von Willebrand Diseases, Von Willebrand Disease (VWD)

  • ALN-6400Phase 22 trials

    Alnylam Pharmaceuticals · Von Willebrand Disease (VWD), Heavy Menstrual Bleeding (HMB), Hereditary Hemorrhagic Telangiectasia

Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.